CymaBay Therapeutics (CBAY) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CymaBay Therapeutics has entered into a merger agreement with Gilead Sciences, whereby Gilead will acquire CymaBay through a cash tender offer, followed by a merger. Shareholders of CymaBay will receive $32.50 per share, with the transaction hinging on customary conditions including a majority of CymaBay’s shares being tendered. The deal also offers cash payouts for certain equity awards at the time of the merger’s effective completion. This strategic acquisition is subject to regulatory approvals, and CymaBay is bound by a no-shop clause with stipulations allowing them to consider superior offers under specific conditions.
For further insights into CBAY stock, check out TipRanks’ Stock Analysis page.